Treatment of triple-negative breast cancer (TNBC), a tumor type defined by lack of expression of ER, progesterone receptor (PR) and epidermal growth factor receptor 2 (HER2), is a challenge as target-specific drugs are not available [2]. This evidence concerns the gene PGR and triple-negative breast carcinoma.